From a company perspective, it is important to understand and acknowledge unmet needs and the key factor for success would be to find solutions for those unmet needs. Can you give an overview of how many companies have joined the Value Added Medicines Group so far? Many companies have joined the Value Added Medicines Group such as 3M, Accord Healthcare, Alfred E. Tiefenbacher, Camargo, Consilient Health Ltd, DSM, EGIS, FRESENIUS KABI, medichem, Mylan, OJER Pharma, Oncomed, Polpharma, SANDOZ, TEVA, Theranexus and ZENTIVA. And today, we have a few others in various stages of the application process. As we interview companies around Europe, many are talking about how artificial intelligence will revolutionize their approach to drug repurposing. What are your thoughts on this game-changer? Digital health and related developments are the realities of today and incorporating digital technologies into Value Added Medicines is inevitable and should be welcomed.